The state of Florida currently has 54 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
Study of AV-1959, an Amyloid Beta Vaccine
NCT05642429
Recruiting
Phase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
02/08/2024
Locations: University of South Florida, Tampa, Florida +1 locations
Conditions: Alzheimer Disease
Register for Updates
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: Advanced Clinical Research Network, Corp, Coral Gables, Florida +12 locations
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Register for Updates
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
NCT05395624
Recruiting
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/01/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Register for Updates
IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's
NCT05543681
Recruiting
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
Gender:
All
Ages:
60 years and above
Trial Updated:
01/05/2024
Locations: Site 700, Melbourne, Florida +2 locations
Conditions: Alzheimer Disease, Agitation,Psychomotor, Depression, Anxiety, Memory Impairment, Care Giving Burden, NPS, Agitated; State, Acute Reaction to Stress, Aggression, Aggressive Outburst
Register for Updates
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
NCT05466422
Recruiting
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar (nM). Optional healthy older participants (Part 2) may receive MK-2214 at dose levels determined by criter... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/03/2024
Locations: Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida +5 locations
Conditions: Alzheimer Disease
Register for Updates
Treatment of Stress and Anxiety in MCI/Mild ADRD
NCT05748613
Recruiting
The goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims to answer are: Efficacy of CAST in reducing anxiety and related symptoms among those with MCI/mild ADRD Efficacy of CAST in reducing care partner burden among care partners of... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
12/13/2023
Locations: Anxiety and Behavioral Health Clinic, Tallahassee, Florida
Conditions: Anxiety, Mild Cognitive Impairment, Alzheimer Disease, Dementia
Register for Updates
ARUA-ALZ - Connecting Audio and Radio SensingmSystems to Improve Care at Home for ADRD
NCT06170528
Recruiting
The purpose of this study is to address the unmet care needs and reduce the care burdens for persons with ADRD (Alzheimer's Disease and Alzheimer's Disease Related Dementias) and their caregivers by providing monitoring of daily activities and gestures using audio and radio sensing, providing voice-based reminders intervention. In phase 1, dyads will participate in two focus groups will take 60 minutes per each. In Phase 2, AURA_ALZ (connecting Audio and Radio Sensing Systems-Alzheimer's Diseas... Read More
Gender:
All
Ages:
Between 18 years and 110 years
Trial Updated:
12/05/2023
Locations: Florida State University College of nursing, Tallahassee, Florida
Conditions: Alzheimer Disease, Caregiver Burden
Register for Updates
Genetic Studies in Familial Dementia
NCT04680013
Recruiting
The purpose of this study is to identify genetic factors that contribute to or cause dementia (loss of memory) and related disorders across all ages and ethnic groups. This includes a number of neurological diseases such as early and late-onset Alzheimer disease, mild cognitive impairment, and other dementias.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/02/2023
Locations: University of Miami, Miami, Florida
Conditions: Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia
Register for Updates
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
NCT06043700
Recruiting
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
11/21/2023
Locations: Eisai Site #1, Lady Lake, Florida +1 locations
Conditions: Alzheimer's Disease
Register for Updates
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
NCT05400330
Recruiting
The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
11/13/2023
Locations: PPD- Orlando Research Unit, Orlando, Florida
Conditions: Alzheimer Disease
Register for Updates
Fasting ENHANCE Pilot Study
NCT05732935
Recruiting
Grounded in the principles of geroscience, the proposed Fasting ENHANCE study will test whether a time restricted eating (TRE) regimen can improve cognitive function and other aspects of successful aging in a safe and sustainable manner in at risk overweight older adults. Specifically, this study will evaluate whether TRE can improve cognitive and physical function, as well as self-reported sleep, mood, and quality of life, in overweight, older adults (age > 65 years) who are at high risk of cog... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
09/06/2023
Locations: Clinical and Translational Research Building - Institute on Aging Suite, Gainesville, Florida
Conditions: Overweight and Obesity, Time Restricted Feeding, Alzheimer Disease
Register for Updates
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301
Recruiting
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
08/30/2023
Locations: Optimus U Corporation, Miami, Florida
Conditions: Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
Register for Updates